Strategically timing inhibition of phosphatidylinositol 3-kinase to maximize therapeutic index in estrogen receptor alpha-positive, PIK3CA-mutant breast cancer

PURPOSE: Phosphatidylinositol 3-kinase (PI3K) inhibitors are being developed for the treatment of estrogen receptor α (ER)-positive breast cancer in combination with anti-estrogens. Understanding the temporal response and pharmacodynamic effects of PI3K inhibition in ER+ breast cancer will provide r...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Clin Cancer Res
Main Authors: Yang, Wei, Hosford, Sarah R., Dillon, Lloye M., Shee, Kevin, Liu, Stephanie C., Bean, Jennifer R., Salphati, Laurent, Pang, Jodie, Zhang, Xiaolin, Nannini, Michelle A., Demidenko, Eugene, Bates, Darcy, Lewis, Lionel D., Marotti, Jonathan D., Eastman, Alan R., Miller, Todd W.
Formato: Artigo
Idioma:Inglês
Publicado: 2016
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4854767/
https://ncbi.nlm.nih.gov/pubmed/26733612
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-2276
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares